News & Events

Immune-Onc Therapeutics Inc. (“Immune-Onc”) is a private, clinical-stage biopharmaceutical company developing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors.

Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development.

We’re excited about our mission and are committed to sharing updates on our progress.

 

Press Releases

Featured
Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting

Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting

Immune-Onc Therapeutics Announces Positive Results from Phase 1 Dose Escalation Study of IO-108 in Advanced Solid Tumors Published in the Journal for ImmunoTherapy of Cancer

Immune-Onc Therapeutics Announces Positive Results from Phase 1 Dose Escalation Study of IO-108 in Advanced Solid Tumors Published in the Journal for ImmunoTherapy of Cancer

Immune-Onc Therapeutics Selected for Oral Presentation at American Society of Hematology (ASH) Annual Meeting to Showcase New Data from Phase 1b Study of IO-202 in Chronic Myelomonocytic Leukemia

Immune-Onc Therapeutics to Present Additional Positive Interim Data From IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress 

Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress 

Immune-Onc Therapeutics to Present Additional Positive Interim Data From IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress 

Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress

Immune-Onc Announces IO-202 CMML Interim Data at EHA2024

Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by USFDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic MyelomonocyticLeukemia (CMML)

Phase 1 study of IO-202 in combination with azacitidine currently enrolling newly diagnosed CMML patients

Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer

Collaboration to evaluate IO-108 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) as a potential first-line therapy for hepatocellular carcinoma

Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023
 

News & Events

Featured
IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia
IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia

IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.

Notable Clinical Benefit and Safety Data with IO-202 Plus Azacitidine in CMML
Notable Clinical Benefit and Safety Data with IO-202 Plus Azacitidine in CMML

For patients with HMA–naive chronic myelomonocytic leukemia, an IO-202 combo demonstrated durable responses, a phase 1b study found.

IO-202/Azacitidine Combo Provides Durable Responses in HMA-Naive CMML
IO-202/Azacitidine Combo Provides Durable Responses in HMA-Naive CMML

Findings from a phase 1b study showed that the combination of IO-202 and azacitidine elicited clinical benefits in patients with hypomethylating agent–naive chronic myelomonocytic leukemia.

Here are some recent breakthroughs by women-led life sciences companies in the Bay Area
Here are some recent breakthroughs by women-led life sciences companies in the Bay Area

Ari Mahrer, data reporter for the San Francisco Business Times, took a look at some of the monumental achievements from companies on their women-led life sciences list. Immune-Onc’s recent milestone: received Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia from the FDA.

IO-202 Receives FDA Orphan Drug Designation for CMML
IO-202 Receives FDA Orphan Drug Designation for CMML

The FDA has granted IO-202 an orphan drug designation for patients with chronic myelomonocytic leukemia.

LLS TAP: Pushing Boundaries and Transforming Lives for Patients with Rare Blood Cancers
LLS TAP: Pushing Boundaries and Transforming Lives for Patients with Rare Blood Cancers

One-hour live moderated discussion with The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) portfolio partners.

Dr Courtney DiNardo Sheds Light on FDA Fast Track Designation and Its Impact on Drug Development
Dr Courtney DiNardo Sheds Light on FDA Fast Track Designation and Its Impact on Drug Development

Courtney DiNardo, MD, MSCE, the lead author on a study presented at EHA 2023 evaluating a new therapy for chronic myelomonocytic leukemia and acute myeloid leukemia, discusses the FDA Fast Track Designation for IO-202 and strategies for raising awareness and improving diversity in clinical trials.

Dr Taylor on Preliminary Efficacy and Safety Data for IO-108 in Advanced Solid Tumors
Dr Taylor on Preliminary Efficacy and Safety Data for IO-108 in Advanced Solid Tumors

Matthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.

 

Media Contact

Tara Cooper
The Grace Communication Group
tara@gracegroup.us